



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

4th September, 2024

Corporate Relationship Department
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400001

The Manager - Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E), Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that in accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release regarding investment of US\$ 8 million by NATCO Pharma (Canada) Inc., Subsidiary Company of NATCO Pharma Limited in eGenesis, Inc., a biotechnology Company.

The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid investment is enclosed as Annexure – I.

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: As above



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/05/2024-25

September 4, 2024

NATCO Pharma (Canada) Inc. announces US\$ 8 million investment in eGenesis, Inc.

NATCO Pharma Limited is pleased to announce that its wholly owned Canadian subsidiary, NATCO Pharma (Canada) Inc., has made an investment of US\$ 8 million in eGenesis, Inc., a biotechnology company at the forefront of xenotransplantation focused on developing safe and effective human-compatible organs for transplant.

In March 2024, eGenesis announced the world's first porcine kidney transplant in a living patient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway.

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure. The eGenesis Genome Engineering and Production (EGEN™) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis is advancing development programs for kidney transplant, acute liver failure, and heart transplant.

"We are excited to get involved with eGenesis, Inc. with respect to their pioneering work in xenotransplantation. We agree with the vision of eGenesis that xenotransplantation technology has the potential to end the global transplant shortage and transforming the treatment of organ failure by eliminating waitlist mortality," said Rajeev Nannapaneni, Vice Chairman and CEO of NATCO Pharma Limited.

"We are thrilled to welcome NATCO as an investor. Their support will be used in advancing our research and bringing our innovative therapies to market," said Mike Curtis, CEO of eGenesis, Inc.

About NATCO Pharma Limited

NATCO Pharma Limited is a vertically integrated pharmaceutical company headquartered in Hyderabad, India. With a strong focus on research and development, NATCO Pharma is dedicated to delivering high-quality, affordable medicines to patients worldwide.

About eGenesis, Inc.

eGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, USA, focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Annexure – I

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Investment of US\$ 8 million in eGenesis, Inc. by NATCO Pharma (Canada) Inc., Subsidiary Company of NATCO Pharma Limited

| Sl. No. | Particulars | Details of Investment |
|---------|--|--|
| A | Name of the target entity, details in brief such as size, turnover etc. | 1) Name of the target entity eGenesis, Inc. 2) Details in brief such as size, turnover etc. It is an R&D company engaged in using its multiplex gene editing and genome engineering platform to research and develop solid organ and therapeutic cell transplantation for the treatment of serious diseases |
| B | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | No |
| C | Industry to which the entity being acquired belongs | Biotechnology |
| D | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | Investing in new-age therapeutic programmes addressing critical unmet medical needs |
| E | Brief details of any governmental or regulatory approvals required for the acquisition | NA |
| F | Indicative time period for completion of the acquisition; | September 30, 2024 |
| G | Nature of consideration - whether cash consideration or share swap and details of the same | Cash consideration |
| H | Cost of acquisition or the price at which the shares are acquired | US\$ 8 million |
| I | Percentage of shareholding / control acquired and / or number of shares acquired | 4,06,29,761 shares |



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

| Sl. No. | Particulars | Details of Investment |
|---------|--|--|
| J | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | <p>1. Brief background:</p> <p>It is engaged in using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.</p> <p>2. Line of business:</p> <p>Biotechnology</p> <p>3. Date of incorporation:</p> <p>October 1, 2015</p> <p>4. Turnover of last 3 years ending December 31 (in US\$ million):</p> <p>Nil</p> <p>5. Country in which the acquired entity will have presence:</p> <p>United States of America</p> |